Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Ltd (CNTB) Covered Calls
Connect Biopharma Holdings Ltd trades in the Biotechnology industry with an IV Rank of 97.22%, high versus the past year. CNTB's highest covered call setup is the $1.00 strike expiring Dec 18, 2026, sorted by theoretical annualized return. It's 47.06% out of the money with 35 days to expiration, a 54.41% return until expiration, and a 567.44% theoretical annualized return. Across the setups shown, annualized returns run from 91.95% to 567.44% at strikes between $1.00 and $1.00, with 35 to 216 days to expiration, as of Nov 13, 2026.
Read more
Running CNTB covered calls helps you generate income from Connect Biopharma Holdings Ltd shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best CNTB covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If CNTB stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling CNTB covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given CNTB covered call is worth writing.
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation.
| 2026-12-18 | 35 | 1.00 | 47.06 | 0.05 | 1.00 | 37.00 | 54.41 | 567.44 | -7.35 | +0.88 | 65 | 0.95 |
| 2027-06-17 | 216 | 1.00 | 47.06 | 0.05 | 1.05 | 37.00 | 54.41 | 91.95 | -7.35 | +0.90 | 0 | 1.00 |
As of Nov 13, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank97.22% High
- Market cap (M$)40
- 52 weeks high-83.25%
- 52 weeks low0.00%
- Analyst recommendationStrong Buy
1.00 - Target price$6.03
842.19% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-16
- P/E—
- Future P/E—
- EPS (ttm)-1.20
- EPS growth next 5 years7.88%
As of Nov 16, 2026